The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis

Guangxian Lu, Jianhua Li, Leyun Ding, Chenping Wang, Lian Tang, Xin Liu, Jinhui Xu, Qin Zhou, Jiantong Sun, Wenjuan Wang, Xinyuan DingFrontiers in Oncology 2021 · DOI

Abstract

Ubiquitin C-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, plays a significant role in cancer chemoresistance. This study investigates its impact on breast cancer (BC), finding that upregulated UCHL1 expression is positively associated with chemoresistance and poor prognosis, particularly in HER2+ subtypes. Mechanistically, UCHL1 promotes resistance to Doxorubicin (DOX) by upregulating free fatty acid (FFA) synthesis. Inhibiting UCHL1 restores DOX sensitivity, suggesting it as a potential clinical target for overcoming resistance in HER2+ BC patients.

Introduction

Breast cancer remains a primary cause of cancer-related deaths among women globally. The HER2-positive (HER2+) subtype is notably aggressive and often treated with Doxorubicin (DOX). However, the development of chemoresistance frequently limits the efficacy of this treatment. Recent research has turned toward deubiquitinating enzymes, specifically Ubiquitin C-terminal hydrolase L1 (UCHL1), as potential drivers of this resistance. While UCHL1's role in other malignancies is documented, its specific metabolic influence on breast cancer chemoresistance has remained largely unexplored until now.

Methods and Datasets

The researchers utilized a local cohort of 54 primary breast cancer tissue samples from the Affiliated Suzhou Hospital of Nanjing Medical University for immunohistochemistry (IHC) analysis. To validate these findings on a larger scale, they accessed the Kaplan-Meier Plotter database, analyzing survival data from hundreds of patients. Experimental models included various BC cell lines (e.g., SK-BR-3, BT474) and a specifically developed DOX-resistant line, MCF-7/DOX. Metabolic changes were tracked using gas chromatography–mass spectrometry (GC–MS) to quantify free fatty acids, alongside Western blotting to measure lipogenic enzymes like FASN and ACACA.

Clinical Correlation of UCHL1 and Chemoresistance

Analysis of the clinical samples revealed a stark correlation between UCHL1 levels and treatment response. Patients with high UCHL1 expression (determined by H-score) were significantly more likely to exhibit resistance to DOX-based chemotherapy ($p = 0.0259$). Furthermore, high UCHL1 levels served as a prognostic "red flag," correlating with poorer recurrence-free and distant metastasis-free survival.

UCHL1 expression correlates with chemotherapy resistance in breast cancer patients.

As shown in the figure above, the distribution of UCHL1 expression (A) and visual IHC staining (B) highlight the variance in patient tissues. The constituent ratio (C) clearly demonstrates that chemoresistant patients have a much higher proportion of UCHL1-high tumors compared to chemosensitive patients.

Mechanistic Insights: Metabolic Rewiring

The study's most groundbreaking finding is the link between UCHL1 and lipid metabolism. UCHL1 appears to hijack cellular pathways to promote lipogenesis—the creation of fats. Specifically, cancer cells with elevated UCHL1 levels produce higher amounts of free fatty acids (FFAs). These FFAs act as a metabolic shield, providing a survival advantage that enables cells to withstand the cytotoxic effects of Doxorubicin.

Crucially, this resistance is reversible. By using the small-molecule inhibitor LDN-57444 to block UCHL1 activity, the researchers observed a significant decrease in the expression of key enzymes like Fatty Acid Synthase (FASN) and a subsequent restoration of DOX sensitivity in previously resistant cell lines.

Conclusion and Future Outlook

This research identifies UCHL1 as a critical mediator of Doxorubicin resistance in HER2+ breast cancer through the upregulation of fatty acid synthesis. By acting as both a prognostic biomarker and a functional driver of metabolic rewiring, UCHL1 presents a dual opportunity for clinical intervention. Future work focusing on in vivo validation and identifying the specific protein substrates of UCHL1 will be essential to translating these findings into effective combination therapies for patients facing chemoresistant breast cancer.

Summary updated

Abstract

Ubiquitin C-terminal hydrolase L1 (UCHL1), which is a deubiquitinating enzyme, is known to play a role in chemoresistance in cancers. However, its potential roles and mechanisms in the chemoresistance of breast cancer (BC) remain unclear. In this study, we examined its expression in patients with BC and employed Kaplan-Meier analysis and the log-rank test for survival analyses. It was found that up-regulated UCHL1 expression was positively associated with both chemoresistance and poor prognosis, especially in patients with HER2+ BC. Moreover, UCHL1 expression was elevated in HER2+ BC cells (SK-BR-3 and BT474). Similarly, doxorubicin (DOX)-resistant BC cells (MCF-7/DOX) had higher UCHL1 levels than MCF-7 cells. CCK-8 assay showed that BC cells with higher UCHL1 levels were more resistant to DOX. Furthermore, by inhibiting UCHL1 in BC cells with elevated UCHL1 expression, we demonstrated that UCHL1 promoted DOX-resistance in BC. Mechanistically, UCHL1 probably promoted DOX-resistance of BC by up-regulating free fatty acid (FFA) synthesis, as exhibited by reduced FFA synthase expression and resurrected DOX-sensitivity upon UCHL1 inhibition. Overall, UCHL1 up-regulation is associated with DOX-resistance and poor prognosis in patients with HER2+ BC. UCHL1 induces DOX-resistance by up-regulating FFA synthesis in HER2+ BC cells. Thus, UCHL1 might be a potential clinical target for overcoming DOX resistance in patients with HER2+ BC.
BibTeX
@inproceedings{lu2021deubiquitinating,
  author = {Guangxian Lu and Jianhua Li and Leyun Ding and Chenping Wang and Lian Tang and Xin Liu and Jinhui Xu and Qin Zhou and Jiantong Sun and Wenjuan Wang and Xinyuan Ding},
  title = {{The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.629640},
}
Figure